Performance of five serological tests in the diagnosis of visceral and cryptic leishmaniasis: a comparative study
The Journal of Infection in Developing Countries · 2023
DOI: 10.3855/jidc.12622 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2023. Verfasst von Martina Maritati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Infectious Diseases and Dermatology Section, University of Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Leishmania, Dog Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Leishmaniasis is a major health problem and its diagnosis still represents a challenge. Since consistent evidence on the comparison of serological methods is lacking, our work aims to compare five serological tests for the diagnosis of visceral and asymptomatic leishmaniasis in southern France, a region where leishmaniasis is endemic. Methodology: Serum samples from 75 patients living in Nice, France were retrospectively analyzed. They included patients affected by visceral leishmaniasis (VL; n = 25), asymptomatic carriers (AC; n = 25) and negative controls (n = 25). Each sample was tested using two immunochromatographic tests (ICT; IT LEISH® and TruQuick IgG/IgM®), an indirect fluorescent antibody test (IFAT) and two Western Blotting (WB; LDBio BIORAD® and an in-house method).
Results
Diagnosis of VL with IFAT and TruQuick® showed the highest diagnostic performance parameters. IFAT had 100% sensitivity and specificity, while TruQuick had 96% sensitivity and 100% specificity. Finally, the two tests showed high accuracy (100% for IFAT and 98% for TruQuick) for the AC group. WB LDBio® was the only method able to detect Leishmania latent infection, with a sensitivity of 92%, and a specificity of 100%, with a Negative Predictive Value (NPV) of 93%. This performance is reflected in the high accuracy of the test.
Conclusions
The data obtained with TruQuick® supports its application in the rapid diagnosis of leishmaniasis in endemic areas, a feature not shown by IFAT despite its high diagnostic performance. Regarding the diagnosis of asymptomatic leishmaniasis, the best results were obtained with WB LDBio®, confirming previous studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Infectious Diseases and Dermatology Section, University of Ferrara, Ferrara, Italy.
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
- Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire l'Archet, INSERM, U1065, C3M, Virulence microbienne et signalisation inflammatoire - Université de la Côte d'Azur, Faculté de Médecine, Centre col…
- Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, Italy.
Zitieren
APA
Maritati, M., Trentini, A., Michel, G., Hanau, S., Guarino, M., De Giorgio, R., Pomares, C., Marty, P., & Contini, C. (2023). Performance of five serological tests in the diagnosis of visceral and cryptic leishmaniasis: a comparative study. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.12622
Vancouver
Maritati M, Trentini A, Michel G, Hanau S, Guarino M, De Giorgio R, et al. Performance of five serological tests in the diagnosis of visceral and cryptic leishmaniasis: a comparative study. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.12622
BibTeX
@article{Maritati2023,
author = {Maritati, Martina and Trentini, Alessandro and Michel, Gregory and Hanau, Stefania and Guarino, Matteo and De Giorgio, Roberto and Pomares, Christelle and Marty, Pierre and Contini, Carlo},
title = {Performance of five serological tests in the diagnosis of visceral and cryptic leishmaniasis: a comparative study},
journal = {The Journal of Infection in Developing Countries},
year = {2023},
doi = {10.3855/jidc.12622}
}
EUVIMED